Head-to-head weight loss: no meaningful advantage
Pooled randomized trials put intermittent fasting and continuous calorie restriction at essentially equal weight loss in adults with overweight or obesity.
The 2026 Cochrane review is the newest synthesis. It finds that intermittent fasting "may result in little to no difference in weight loss" compared with traditional dietary advice (21 studies, 1430 people). Its confidence is low because most studies were small and not robustly conducted; it is moderately confident only about fasting compared with no treatment. Two other syntheses agree:
- A 167-trial network meta-analysis of 11 998 participants found most fasting regimens produced weight loss comparable with continuous restriction at a similar absolute energy restriction.
- A meta-analysis of longer-term trials concluded the two are comparably effective for weight and adiposity in adults with overweight or obesity.
These three syntheses draw on different trial sets and reach the same answer. That makes equivalence the stable reading, even though Cochrane's certainty is low.1,2,3,4
Throughout, differences are given as fasting minus continuous restriction, so a negative number means more loss on fasting. A 2023 meta-analysis of 28 trials lasting 2-52 weeks pooled time-restricted eating, alternate-day fasting and the 5:2 diet. The combined weight difference was -0.42 kg (95% CI -0.96 to 0.13; P = 0.132). On these inputs, the interval rules out a fasting advantage of more than about 1 kg for fasting diets taken together. The same pooling found slightly greater waist reduction on fasting (-0.91 cm), discussed with body composition below.5
By strategy: only alternate-day fasting shows an edge, and it is small
Alternate-day fasting beats continuous restriction by about 1.3 kg in pooled analyses. The other strategies do not:
- Time-restricted eating means eating only within a daily window.
- Whole-day fasting covers 5:2-type schedules with full fasting days each week.
The largest network meta-analysis compared each diet with ad-libitum (unrestricted) eating. Alternate-day fasting gave -3.40 kg (high certainty), whole-day fasting -2.36 kg (high certainty), continuous restriction -2.11 kg (moderate certainty) and time-restricted eating -1.72 kg (moderate certainty). Against continuous restriction directly, only alternate-day fasting added loss: -1.29 kg (95% CI -1.99 to -0.59), at moderate certainty. Time-restricted eating and whole-day fasting did not differ from each other.6
Mean difference in body weight vs ad-libitum eating (kg) by diet
Source: Semnani-Azad et al., BMJ 2025;389:e082007, network meta-analysis (18 Jun 2025)
The alternate-day fasting edge falls below the clinical-relevance level. The review's authors say the -1.29 kg comparison "fell below this level", suggesting limited clinical impact. The accompanying BMJ editorial gives that threshold as at least 2 kg for people with obesity. Our calculation: 1.29 kg is about 65% of 2 kg. Even the far end of the confidence interval, -1.99 kg, does not reach the threshold.7,8
An umbrella review of meta-analyses points the same way. Its high-quality associations comparing fasting (alternate-day, time-restricted, whole-day) with continuous restriction show no significant effect on weight or BMI. Moderate-quality associations show small advantages for whole-day or modified alternate-day fasting:
- -0.55 kg (95% CI -1.01 to -0.09)
- -1.37 kg (95% CI -2.24 to -0.49)
- -0.95 kg (95% CI -1.63 to -0.27)
Read together, these suggest at most a small effect.9,10,11
Most 12-month head-to-head trials are null. The one exception ran in an unusual setting.
| Trial (12 months) | Adults | Result, fasting vs continuous restriction | What it means |
|---|---|---|---|
| Time-restricted eating (8 h) plus calorie restriction vs calorie restriction alone | 139 with obesity | -8.0 kg vs -6.3 kg; net -1.8 kg (95% CI -4.0 to 0.4; P=0.11) | Null; interval too wide to prove equivalence |
| Alternate-day fasting vs daily calorie restriction | 100 metabolically healthy with obesity | 6.0% vs 5.3% loss relative to control; not significantly different | Null |
| 4:3 intermittent fasting vs daily calorie restriction | 165 with overweight or obesity | Mean difference 2.89 kg (95% CI 5.65 to 0.14 kg; P = 0.040) in favour of 4:3 | Modest benefit, inside an intensive programme |
The time-restricted eating trial was designed to detect a 2.5 kg difference. Its interval neither confirms nor excludes a benefit of that size, so it is a null result rather than proof of equivalence. Its intervals were not adjusted for multiple comparisons. Its authors concluded that time-restricted eating was not more beneficial than daily calorie restriction for weight, body fat or metabolic risk factors.15,16,17
In the 4:3 trial, the fasting group cut intake by 80% on 3 nonconsecutive days a week. The comparison group cut daily intake by 34% to match the weekly deficit. Both groups also had a high-intensity behavioural programme, with a target of 300 minutes of activity a week. The authors call the gain modest and note limited generalizability. With a lower bound of 0.14 kg, a single trial in this setting does not overturn the pooled equivalence.18,19
Energy deficit, not meal timing, drives the result
Where fasting arms lose more, they usually also ate less. With intake matched, weight loss is similar. The 167-trial network meta-analysis concludes that in adults with overweight, obesity or metabolic abnormalities, effectiveness "mainly depends on the extent of the energy restriction, regardless of the mealtime patterns."20
Unmatched intake tilts trials toward fasting. In the 2023 meta-analysis, every study that reported a difference in intake found a larger deficit in the fasting arm, sometimes a large one. On these inputs, that bias favours fasting, yet the pooled weight difference stayed non-significant.21
A trial in type 2 diabetes shows the same pattern. Its time-restricted arm ate freely within an 8-hour window, without counting calories. Its comparison arm cut intake by 25% of baseline needs. Yet the time-restricted arm achieved the larger deficit: -313 kcal/d against -197 kcal/d. Its numerically greater loss therefore reflects intake, not timing.22,23,24
When deficits were similar, outcomes converged:
- In the 1-year alternate-day fasting trial, the fasting arm restricted energy by 21% and the continuous arm by 24% over six months, with no significant difference, and weight loss did not differ.
- In a trial with overall restriction matched at 33% in both arms, both lost about 12.5% of body weight.25,26,27
A review limited to trials with matched energy intakes found similar weight loss and risk-factor effects for fasting and daily restriction. It judged hints of better fat loss and insulin sensitivity on fasting too limited to support conclusions. A 2025 meta-analysis of isocaloric trials reached the same verdict: fasting "may be an effective alternative to CR but is not superior."28,29
Duration and maintenance: any edge fades with time
In trials of 24 weeks or more, no fasting strategy outperforms continuous restriction. The largest network meta-analysis split trials by length:
- In the 76 trials under 24 weeks, alternate-day fasting beat continuous restriction by -1.29 kg (95% CI -2.05 to -0.53).
- In the 17 trials of 24 weeks or more, there were no differences between fasting strategies and continuous restriction.30
Whether fasting is worse at keeping weight off is unsettled. The 167-trial analysis found in a subgroup analysis that weight loss on fasting, but not on continuous restriction, rebounded after 12 weeks. Individual trials do not show this:
- In the alternate-day fasting trial, regain from month 6 to 12 did not differ between arms (-0.8%; 95% CI -3.2% to 1.7%).
- In a type 2 diabetes trial, both arms held their 3-month loss at 12 months: 0.4 kg regained on continuous restriction, -0.2 kg on intermittent restriction (P = .48).31,32,33
The longest follow-up is from a randomized trial in adults with overweight or obesity. At week 102, weight change was -4.3% on intermittent calorie restriction and -5.0% on continuous restriction, which was not significantly different. Weight at that point was self-reported by telephone, although earlier self-reports matched measured weights. Between week 50 and week 102, 71.1% of the intermittent group had not continued or only rarely continued their diet, against 32.5% of the continuous group.34,35,36
Long-term evidence is scarce. Only five trials in the largest network meta-analysis reached 52 weeks or more. Cochrane's included studies ran up to 12 months. The 2023 meta-analysis included no trial longer than a year.37,38,39
Populations: a small pooled edge in diabetes, little evidence in healthy-weight adults
In prediabetes or type 2 diabetes, a pooled advantage for fasting appears, but individual diabetes trials are not significant. A 2024 meta-analysis found fasting reduced weight by -1.14 kg (95% CI -1.69 to -0.60) and BMI by -0.43 kg/m² compared with calorie restriction. It did not change fat mass, HbA1c, lipids or blood pressure.40
Two diabetes trials both point to roughly 1.8 units more loss on fasting, without significance:
- Intermittent energy restriction, 12 months: the weight difference was -1.8 kg (90% CI -3.7 to 0.07). Weight loss was "similar" but failed the equivalence test. HbA1c fell similarly (-0.5% vs -0.3%) and met equivalence.
- Time-restricted eating, 6 months: the authors summarise this trial as finding time-restricted eating "more effective" (-3.6% vs -1.8%), but both figures are relative to controls. The direct difference was -1.78% of body weight (95% CI -4.09 to 0.53), not significant against the Bonferroni threshold of P < .017.
Both trials are consistent with the small pooled edge.41,42,43,44
The largest network meta-analysis ran a sensitivity analysis in 11 type 2 diabetes trials. Against ad-libitum eating, alternate-day fasting gave a moderate reduction (-4.42 kg), whole-day fasting -2.74 kg, continuous restriction -2.87 kg and time-restricted eating -1.93 kg.45
Most of the evidence comes from people with overweight or obesity. That analysis pooled 6582 participants with a median BMI of 31.3, of whom 720 were healthy and 5862 had existing conditions. Single trials often exclude important groups: the 12-month time-restricted eating trial cannot be generalized to people with diabetes or cardiovascular disease, or to other ethnic groups.46,47
Secondary outcomes: small body-composition differences, similar metabolic markers
Fasting may trim waist and fat mass slightly more than continuous restriction, but it also removes slightly more fat-free (lean) mass. Glucose, insulin, lipids and blood pressure largely do not differ.
| Measure | Fasting vs continuous restriction | What it means |
|---|---|---|
| Waist, alternate-day fasting | -1.19 cm (95% CI -2.13 to -0.24), moderate certainty | Slight extra waist reduction |
| BMI, alternate-day fasting | -0.52 (95% CI -0.85 to -0.19), moderate certainty | Mirrors the small weight edge |
| Fat mass, trials of all lengths | -0.31 kg (95% CI -0.98 to 0.36), not significant | No difference overall |
| Fat mass, time-restricted eating subgroup | -0.91 kg (95% CI -1.63 to -0.18; k = 4) | Small, few trials |
| Fat mass, longer-term trials in overweight/obesity | -0.70 kg; body fat -0.59% | Small advantage in one pooled set |
| Fat-free mass | -0.20 kg (95% CI -0.39 to -0.01) | Slightly more lean loss on fasting |
| Fasting glucose | -0.01 mmol/L (95% CI -0.08 to 0.05) | No difference |
| Fasting insulin | -0.17 μIU/mL (95% CI -0.82 to 0.47) | No difference |
| HOMA-IR (insulin resistance), alternate-day fasting | -0.73 (95% CI -1.43 to -0.03; k = 4) | One small subgroup benefit |
| Triglycerides, total, HDL and LDL cholesterol | All non-significant | No difference |
| Blood pressure | Systolic -0.48 mm Hg, diastolic -0.67 mm Hg, not significant; diastolic -0.91 mmHg and HDL +0.03 mmol/l in longer-term trials | Mostly no difference |
Fat-mass advantages are inconsistent. They appear in some pooled sets but not in the 1-year alternate-day fasting trial. That trial found no differences in fat mass, lean mass or visceral fat at 6 or 12 months.54
That trial also found no differences in blood pressure, glucose, insulin or triglycerides. However, LDL cholesterol was 11.5 mg/dL (95% CI 1.9-21.1 mg/dL) higher at month 12 on alternate-day fasting than on daily restriction. HDL cholesterol rose at 6 months but not at 12.55
One umbrella-review association covering 1438 adults with overweight or obesity found fasting less effective at lowering systolic pressure (SMD = 0.21; 95% CI 0.05-0.36).56
A pooling of isocaloric trials found fasting cut fat mass and IL-6 (an inflammation marker) in the short term. In the long term it improved body fat percentage, waist, fasting insulin and HOMA-IR. On the other side, continuous restriction brought significantly lower hunger, fatigue and triglycerides.57
Adherence and dropout: no advantage for fasting
Adherence falls on both approaches over a year. Fasting arms show equal or higher dropout.
| Trial | Fasting arm | Continuous restriction arm | What it means |
|---|---|---|---|
| Alternate-day fasting, 1 year, dropout | 13 of 34 (38%) | 10 of 35 (29%); control 26% | Highest dropout on fasting |
| Intermittent energy restriction in type 2 diabetes, 12 months, dropout | 19 (27.1%) | 21 (31.3%); P = .71 | Similar |
| Same diabetes trial, compliance | 97% in first 3 months, then 44% | 90%, then 49% | Both decline sharply |
| Whole-day fasting trial in the largest network meta-analysis, adherence | 74% at 6 weeks, 22% at 52 weeks | Not given | Steep long-run decline |
| Time-restricted eating in type 2 diabetes, 6 months | Eating window kept on 87% of days | 68% of participants met calorie goals | Fasting reported as easier |
Most trials in the largest network meta-analysis report high adherence of over 80%. However, most of its 52-week trials described poor adherence in the intervention groups.
In the 1-year alternate-day fasting trial, more continuous-restriction participants met their energy goals at months 3, 6, 9 and 12. Fasting participants ate more than prescribed on fast days and less than prescribed on feast days. On this evidence, fasting schedules can be harder to follow precisely, even where some people find them simpler.63,64
How far to trust the evidence
The finding that the two approaches are equivalent holds across syntheses, but individual estimates are imprecise. The largest network meta-analysis judged more than 80% of its trials at low risk of bias. Even so, it downgraded certainty for several reasons:
- Heterogeneity: unexplained differences between trial results.
- Incoherence: direct and indirect comparisons disagreeing.
- Imprecision from small samples.
- Indirectness: only three trials compared fasting strategies with each other directly.
Its median follow-up was 12 weeks, with a range of 3-52 weeks.65,66,67
Judgements of bias differ between reviews, and the difference matters. The 2023 meta-analysis rated 82.8% of its trials as having some bias concerns. This was mainly because trials did not report whether outcome assessors knew the participants' diet. Participants always knew their arm, since every study involved an energy-restricted diet. A 2021 umbrella review rated most associations at very serious risk of bias, partly because masking is impossible when two diets are compared. It also noted a median trial size of 38 participants, a median follow-up of 3 months, and significant findings resting mostly on very low to low quality evidence. The low-bias rating should therefore be read as "no serious flaws beyond the unavoidable", not as blinded-trial quality.68,69,70
What the sources gathered do not establish
- Whether the comparison holds in healthy-weight adults. There is no separate estimate for them, so advice for people not trying to treat overweight rests on extrapolation.
- Whether intermittent fasting helps or hinders keeping weight off beyond 12 months. Few trials reach 52 weeks, and the 102-week data are self-reported. This is the question that matters most for long-term choice.
- The pooled difference in weight loss as a percentage of body weight. The syntheses report kilograms only, which makes it harder to compare results across people of different sizes.
- Exactly how each regimen and its comparator were defined in the largest network meta-analysis. That bears on whether its alternate-day fasting edge reflects calorie-matched arms or a larger deficit.
- Whether the short-term alternate-day fasting advantage persists when energy intake is strictly matched. If it does not, the one strategy-specific edge would be explained entirely by eating less.